In Vitro Metabolism and Non-Clinical ADME Studies

The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health, is soliciting proposals for in vitro metabolism and non-clinical absorption, distribution, metabolism, and excretion (ADME) studies. This procurement, identified by solicitation number N01DA-21-8957, falls under NAICS code 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN11 for Health R&D Services; Health Care Services; Basic Research. The agency intends to award a single, indefinite delivery, indefinite quantity (IDIQ) contract to support drug development programs, with an initial performance period beginning on or around September 2021 and lasting five years.

The resulting contract includes a guaranteed minimum of $100,000 and an estimated maximum quantity of $3,500,000. Task orders issued under this IDIQ may be fixed-price and categorized as completion, severable, or non-severable depending on program needs. Proposals must include separate technical and cost/price components for each of the fourteen items specified in the Statement of Work. This solicitation process is governed by the Uniform Contract Format, and an amendment was issued on March 3, 2021, to provide clarifications based on submitted questions.

The deadline for responses is March 29, 2021, for performance occurring within the United States. Polina Klimenkova serves as the primary point of contact for this requirement. The solicitation package includes three official attachments: the original RFP document, an updated Statement of Work, and Amendment 01. Metadata indicates the notice was first published on February 12, 2021, and received its final update on March 3, 2021.